Fig. 3: Treatment activity based on baseline gene expression. | npj Breast Cancer

Fig. 3: Treatment activity based on baseline gene expression.

From: Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Fig. 3

a Genes found differentially expressed in baseline samples between pCRB and no-pCRB in SAM analysis. Colored dots mark the genes with a false discovery rate (FDR) = 0, in red upregulate and in green downregulated. b Association of 11 gene signatures (as a continuous variable) with pCR adjusted for cohort (TNBC and HR-positive). Each signature was evaluated as a continuous variable and was standardized to have a mean of 0 and a SD of 1. The size of the square is inversely proportional to the standard error; horizontal bars represent the 95% confidence intervals (CI) of Odd ratios. Statistically significant variables are shown in pink. c PAM50 signature expression at baseline according with pathologic complete response (pCR) or residual disease (non-pCR) at surgery. p-value was obtained after performing ANOVA test. Error bars correspond to standard error of the mean.

Back to article page